Pharma BD Deal Intelligence

Grifols, S.A. / Talecris Biotherapeutics Holdings Corp.

2011 · Acquisition/Merger · $3.4B · Complete

Announcement Sentiment

Positive

Grifols completed its $3.4B (~$4.0B with debt) acquisition of US plasma-protein therapeutics maker Talecris on June 1, 2011, creating a global plasma-products leader. FTC required divestitures including the Melville fractionation plant.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jun 01, 2011
Closed Jun 01, 2011
Deal value $3.4B
Deal type Acquisition/Merger
Therapeutic area Primary immune deficiency, alpha-1 antitrypsin deficiency, hemophilia, ICU/critical care
Indications Primary immune deficiency, alpha-1 antitrypsin deficiency, hemophilia, ICU/critical care
Key assets Plasma-derived therapies (IVIG/Gamunex, albumin, alpha-1 antitrypsin Prolastin)
Mechanism Plasma fractionation; immunoglobulins, clotting factors, protease inhibitors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals